|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Positive RSF1 expression was associated with advanced tumour stage, high Gleason grade, lymph node metastasis (<i>p</i> < .0001 each), early biochemical recurrence (<i>p</i> < .0003) and more frequent in the ERG positive than in the ERG negative subset (88% versus 71%; <i>p</i> < .0001).
|
31687881 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
FABP5 overexpression is frequent in PCa, but seems to be restricted to TMPRESS2:ERG fusion-negative tumors and is associated with SPOP and FOXA1 mutations.
|
30701334 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer.
|
31745645 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The loss of PSP94 expression was inversely correlated to EZH2 expression (<i>P</i> < 0.0001) and largely unrelated to the ERG status, but strongly correlated with high Gleason grade, advanced tumor stage, and nodal metastasis ( <i>P</i> <0.0001 each).
|
31516752 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The pair miR-145/ERG showed an exclusive staining for miR-145 in the nuclei of stromal cells, both in tumor and normal tissue, and for ERG in the cytoplasm with/without co-expression in the nucleus of tumor cells.
|
31186527 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lower ERG expression in dural and intraparenchymal metastases suggests a possibility that ERG-negative tumors with loss of MAP3K7 may become resistant to standard therapies and diffusely metastasize.
|
30656528 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Based on PTEN and ERG status, iIDC-P is not likely a precursor to the associated low-grade invasive PCa, but represents a molecularly unique in situ tumor of unclear clinical significance.
|
30993692 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In all 21 cases harboring both alterations, the tumor area containing a 5q21 deletion was smaller or equally large than the ERG-positive area but never larger.
|
30623509 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Their tumor epithelial cells were often ERG positive and expressed higher levels of ErbB2, phosphorylated epidermal growth factor receptor (pEGF-R) and protein kinase B (pAkt), and their tumor stroma showed a reactive response with type 2 macrophage infiltration, high density of blood vessels and hyaluronic acid, and with reduced levels of caveolin-1, androgen receptors, and mast cells.
|
30980038 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We hypothesize that enzalutamide treatment will be more effective in cells/tumors with TMPRSS2-ERG translocations because these tumors have increased AR signaling.
|
31638934 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
5hmC Level Predicts Biochemical Failure Following Radical Prostatectomy in Prostate Cancer Patients with ERG Negative Tumors.
|
30818754 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In addition, loss of S100A8 expression was associated with TMPRSS2:ERG fusions (P < .0001), deletions of PTEN, 3p, and 6q (P < .005), and a high number of genomic deletions per tumor (P = .0009).
|
31382165 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Of all the 106 ERG-positive cases, eight cases (7.5%) exhibited heterogeneous expression of ERG protein, in which ERG was only positive in tumors with Gleason pattern 3, but negative in Gleason pattern 4.
|
30900303 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor ERG positivity and PTEN loss were associated with more extensive residual tumors at RP.
|
30811282 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SPOP or FOXA1 alterations (mutations or expression loss) were significantly more common in GG5, while isolated ERG overexpression was more common in GG1 tumors (P = 0.042).
|
31090082 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ERG expression showed no significant correlation with DLBCL cell-of-origin classification, patient's age, sex, nodal, or extranodal disease status, tumor expression of p53 or p63.
|
31237044 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Separate calculations in 3854 cancers with and 4768 cancers without <i>TMPRSS2:ERG fusion</i> revealed that these associations with tumor phenotype and patient outcome were largely driven by the subset of ERG-negative tumors.
|
31296150 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here we report a frequency of 13% for TMPRSS2-ERG in tumors from Black South Africans.
|
31090091 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Patient characteristics, clinical factors, and tumor expression of ERG by immunohistochemistry were analyzed with respect to therapeutic response and survival data.
|
30679082 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemically, the tumor showed diffuse nuclear staining of ERG.
|
31376366 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CEBPA is down regulated in about one third of prostate cancers, but the clinical impact of CEBPA loss is strictly limited to the subset of about 10% prostate cancers carrying both ERG fusion and deletions of the PTEN tumor suppressor.
|
30430607 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This study aimed to investigate if combined analysis of pro-Neuropeptide Y (NPY) and ERG expression in tumor tissue are associated with biochemical failure (BF), castration-based treatment, castration-resistant prostate cancer (CRPC), and prostate cancer (PCa)-specific death for men undergoing radical prostatectomy (RP) for PCa.
|
30191621 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A comparison with other molecular tumor features available from earlier studies revealed that TMPRSS2-ERG fusion as well as deletion of PTEN, 5q21, 6q15, and 3p13 was less frequent in IDH1-mutated than in non-mutated cancer.
|
29427004 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Further, by genome-wide mapping of cyclobutane pyrimidine dimers (CPDs) shortly after UV exposure and thus before DNA repair, we find that ETS-related mutation hotspots exhibit strong increases in CPD formation efficacy in a manner consistent with tumor mutation data at the single-base level.
|
30586386 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
There was a significant interplay between ERG and PTEN expression with 21.8% PTEN negative tumors being ERG positive (p < 0.001).
|
30101374 |
2018 |